453 related articles for article (PubMed ID: 17964011)
1. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
Ferrier-Rembert A; Drillien R; Meignier B; Garin D; Crance JM
Vaccine; 2007 Nov; 25(49):8290-7. PubMed ID: 17964011
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2008 Mar; 26(14):1794-804. PubMed ID: 18336966
[TBL] [Abstract][Full Text] [Related]
3. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
4. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
5. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
6. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and genetic diversity of the traditional Lister smallpox vaccine.
Garcel A; Perino J; Crance JM; Drillien R; Garin D; Favier AL
Vaccine; 2009 Jan; 27(5):708-17. PubMed ID: 19059294
[TBL] [Abstract][Full Text] [Related]
9. Intranasal cowpox virus infection of the mouse as a model for preclinical evaluation of smallpox vaccines.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2007 Jun; 25(25):4809-17. PubMed ID: 17499401
[TBL] [Abstract][Full Text] [Related]
10. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
[TBL] [Abstract][Full Text] [Related]
11. Real time PCR for the assessment of CD8+ T cellular immune response after prophylactic vaccinia vaccination.
Trojan A; Rajeswaran R; Montemurro M; Mütsch M; Steffen R
J Clin Virol; 2007 Sep; 40(1):80-3. PubMed ID: 17644471
[TBL] [Abstract][Full Text] [Related]
12. The persistence of humoral and cellular immunities more than three decades after smallpox vaccination.
Kim SH; Yeo SG; Park KH; Bang JW; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW
Clin Microbiol Infect; 2007 Jan; 13(1):91-3. PubMed ID: 17184294
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
14. Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice.
Melamed S; Paran N; Katz L; Ben-Nathan D; Israely T; Schneider P; Levin R; Lustig S
Vaccine; 2007 Nov; 25(45):7743-53. PubMed ID: 17928110
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain.
Hsieh SM; Chen SY; Sheu GC; Hung MN; Chou WH; Chang SC; Hsu KH
Vaccine; 2006 Jan; 24(4):510-5. PubMed ID: 16139395
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P
Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a vaccinia virus strain used to produce smallpox vaccine in Argentina between 1937 and 1970.
Lewis A; Bok K; Perez O; DeFillippo J; Paolazzi C; Gomez JA
Arch Virol; 2005 Jul; 150(7):1485-91. PubMed ID: 15750861
[TBL] [Abstract][Full Text] [Related]
18. Bioterrorism. Smallpox vaccinations: how much protection remains?
Cohen J
Science; 2001 Nov; 294(5544):985. PubMed ID: 11691969
[No Abstract] [Full Text] [Related]
19. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Meseda CA; Weir JP
Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482
[TBL] [Abstract][Full Text] [Related]
20. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.
Weltzin R; Liu J; Pugachev KV; Myers GA; Coughlin B; Blum PS; Nichols R; Johnson C; Cruz J; Kennedy JS; Ennis FA; Monath TP
Nat Med; 2003 Sep; 9(9):1125-30. PubMed ID: 12925845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
